ResMed

RMD

Market cap $32.7B

RMD's growth strategy, rising device demand and solid finances support momentum, but macro pressures and stiff competition could test its outlook.

SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2026 on Thursday, April 30, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.

Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. NVDA, RL, RMD and GE hold promise.

ResMed (RMD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

ResMed (RMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

RMD expands mask and device sales while maintaining strong liquidity, but macro and competitive pressures loom.

The heavy selling pressure might have exhausted for ResMed (RMD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

ResMed has been growing, and investing in further growth as well -- especially via digital technologies. Its stock is appealingly priced at recent levels.

Insights from 30,000 people across 13 countries show global sleep health awareness is growing, yet an action gap remains  53% of people surveyed rank sleep as the most important behavior for a long, healthy life, ahead of diet and exercise. Over half of respondents get quality sleep on only four nights a week or less.

ResMed (RMD) stock is currently at a fascinating juncture. It is trading at a low price, and if you decide to invest in it, you are wagering on a company that is demonstrating reasonable growth, maintaining solid cash flow and margin, has a low-debt capital structure, and is fairly valued.